BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/24/2021 9:48:20 AM | Browse: 491 | Download: 1201
 |
Received |
|
2021-04-27 11:05 |
|
Peer-Review Started |
|
2021-04-27 11:07 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-13 03:47 |
|
Revised |
|
2021-06-22 08:36 |
|
Second Decision |
|
2021-12-10 06:13 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-12-10 22:57 |
|
Articles in Press |
|
2021-12-10 22:57 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-10-27 08:01 |
|
Typeset the Manuscript |
|
2021-12-17 04:02 |
|
Publish the Manuscript Online |
|
2021-12-24 09:48 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiao-Cui Wei, Ya-Ru Xia, Ping Zhou, Xing Xue, Li-Juan Liu, Shuang Ding and Fan Zhu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81971943 |
| the Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University |
TFJC 2018002 |
| National Natural Science Foundation of China |
81772196 |
|
| Corresponding Author |
Fan Zhu, PhD, Professor, State Key Laboratory of Virology, Hubei Province Key Laboratory of Allergy and Immunology, Department of Medical Microbiology, School of Medicine, Wuhan University, No. 185 Donghu Road, Wuhan 430071, Hubei Province, China. fanzhu@whu.edu.cn |
| Key Words |
Hepatocellular carcinoma; Exosomes; miR-135a-5p; Anti-apoptosis; Proliferation; Chemoresistance |
| Core Tip |
Hepatitis B virus infection is the most common cause of hepatocellular carcinoma (HCC). Drug resistance is the primary reason for the high mortality of HCC patients. We demonstrated that hepatitis B core antigen (HBc) increased exosomal miR-135a-5p. Tissue samples showed that the level of miR-135a-5p was significantly elevated in HCC tissues. Vesicle-associated membrane protein 2 (VAMP2) was demonstrated to be a target gene of miR-135a-5p. Further investigation recommended that HBc enhanced the anti-apoptosis, cell proliferation, and chemotherapy resistance of HCC cells through exosomal miR-135a-5p by targeting VAMP2. Our findings reveal that HBc can cause anti-cancer drug resistance in HCC and provide us with a novel mechanism underlying drug resistance in cancer chemotherapy. |
| Publish Date |
2021-12-24 09:48 |
| Citation |
Wei XC, Xia YR, Zhou P, Xue X, Ding S, Liu LJ, Zhu F. Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma. World J Gastroenterol 2021; 27(48): 8302-8322 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i48/8302.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i48.8302 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
